SCHEMBL1418463

SCHEMBL1418463

CN1CCOc2cc(C=O)ccc21

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.53
MEN1 O00255 1/20 0.53
GAA P10253 1/20 0.53
MAPT P10636 1/20 0.53
HPGD P15428 1/20 0.53
KMT2A Q03164 1/20 0.53
NOTUM Q6P988 1/20 0.48
CYP11B1 P15538 1/20 0.48
CYP11B2 P19099 1/20 0.48
HTT P42858 1/20 0.46
RECQL P46063 1/20 0.46
HSD17B10 Q99714 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
ALDH1A3 P47895 5/20 0.45
ALDH3A1 P30838 1/20 0.45
MYC P01106 1/20 0.44
TRPM5 Q9NZQ8 1/20 0.43
PTGES2 Q9H7Z7 1/20 0.43
AR P10275 1/20 0.42
GRM5 P41594 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30186040 1.00 ALDH1A1 (0.53) ALDH1A1MEN1GAAMAPTHPGD
SCHEMBL7353819 0.90 ALDH1A1 (0.51) ALDH1A1MEN1GAAMAPTHPGD
SCHEMBL21872800 0.84 CYP11B1 (0.48) ALDH1A1MAPTNOTUMCYP11B1CYP11B2
SCHEMBL14744979 0.81 MYC (0.50) ALDH1A1MEN1MAPTHPGDKMT2A
SCHEMBL14744980 0.81 MYC (0.50) ALDH1A1MEN1MAPTHPGDKMT2A
SCHEMBL16440970 0.81 MYC (0.50) ALDH1A1MEN1MAPTHPGDKMT2A
SCHEMBL6177816 0.80 ALDH1A1 (0.42) ALDH1A1MEN1GAAMAPTHPGD
SCHEMBL11143387 0.80 ALDH1A1 (0.42) ALDH1A1MEN1GAAMAPTHPGD
SCHEMBL11142403 0.78 ALDH1A3 (0.43) ALDH1A1MEN1GAAMAPTHPGD
SCHEMBL9141312 0.77 ALDH1A1 (0.64) ALDH1A1MEN1GAAMAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 176 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4580750-A1 SORTILIN MODULATORS Vesper Bio Aps (DK) 2025-07-09 EP disclosed
US-11958837-B2 Quinazolinones as PARP14 inhibitors RIBON THERAPEUTICS, INC. (US) 2024-04-16 US disclosed
EP-4342530-A1 SORTILIN MODULATORS Insusense ApS (DK) 2024-03-27 EP disclosed
WO-2024047227-A1 SORTILIN MODULATORS INSUSENSE ApS (DK) 2024-03-07 WO disclosed
EP-4212515-A1 QUINAZOLINONES AS PARP14 INHIBITORS Ribon Therapeutics Inc. (US) 2023-07-19 EP disclosed
EP-3405477-B1 INHIBITORS OF TRANSGLUTAMINASES ZEDIRA GMBH (DE) 2023-06-07 EP disclosed
US-20230141569-A1 FLUORESCENT DYE, AND PREPARATION METHOD AND USES THEREOF FLUORESCENCE DIAGNOSIS (SHANGHAI) BIOTECH COMPANY LTD. (CN) 2023-05-11 US disclosed
US-20230141569-A1 FLUORESCENT DYE, AND PREPARATION METHOD AND USES THEREOF FLUORESCENCE DIAGNOSIS (SHANGHAI) BIOTECH COMPANY LTD. (CN) 2023-05-11 US disclosed
US-11603349-B2 Anti-fibrotic compounds CERTA THERAPEUTICS PTY LTD (AU) 2023-03-14 US disclosed
WO-2023011657-A1 METHOD FOR DETECTING AND QUANTIFYING RNA 纳莹(上海)生物科技有限公司 2023-02-09 WO disclosed
US-6143746-A Combination of tadalafil and another drug for cGMP-specific PDE inhibition; erectile dysfunction, cardiovascular disorders ICOS CORPORATION (US) 2000-11-07 US disclosed
US-6127542-A CHEMICAL INTERMEDIATES TO SPECIFIED PYRAZINO(2',1':6,1)PYRIDO(3,4B)INDOLE-1,4-DIONES WHICH ARE SELECTIVE INHIBITORS OF CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE SPECIFIC PHOSPHODIESTERASE; TO TREAT CARDIOVASCULAR DISORDERS ICOS CORPORATION (US) 2000-10-03 US disclosed
US-6025494-A CYCLIZATION OF DICARBONYL-SUBSTITUTED PYRIDOINDOLES YIELDS PHOSPHODIESTERASE INHIBITORS ICOS CORPORATION (US) 2000-02-15 US disclosed
US-5859006-A CYCLIZATION; AMIDATION; SELECTIVE INHIBITOR OF CYCLIC GUANOSINE 3',5'-MONOPHOSPHATASE SPECIFIC PHOSPHODIESTERASE; USEFUL IN THE TREATMENT OF CARDIOVASCULAR DISORDERS; TADALAFIL CLAIMED ICOS CORPORATION (US) 1999-01-12 US disclosed
EP-0740668-B1 TETRACYCLIC DERIVATIVES, PROCESS OF PREPARATION AND USE ICOS CORP (US) 1998-07-29 EP disclosed
EP-0740668-A1 TETRACYCLIC DERIVATIVES, PROCESS OF PREPARATION AND USE LABORATORIES GLAXO WELLCOME S.A. (FR) 1996-11-06 EP disclosed
WO-1995019978-A1 TETRACYCLIC DERIVATIVES, PROCESS OF PREPARATION AND USE LABORATOIRES GLAXO WELLCOME S.A. (FR) 1995-07-27 WO disclosed
EP-0037374-B1 METHINIC COMPOUNDS CIBA-GEIGY AG (CH) 1983-12-28 EP disclosed
US-4403095-A DYEING POLYACRYLONITRILES CIBA-GEIGY CORPORATION (US) 1983-09-06 US disclosed
EP-0037374-A2 Methinic compounds CIBA-GEIGY AG (CH) 1981-10-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11958837-B2 Quinazolinones as PARP14 inhibitors PARP14, PARP15, PARP11 ALDH1A1 2388/4885MEN1 2734/4885GAA 3263/4885
US-11603349-B2 Anti-fibrotic compounds TGFB1, SMAD3, TGFB2 ALDH1A1 1274/4885MEN1 3362/4885GAA 1453/4885
US-20230141569-A1 FLUORESCENT DYE, AND PREPARATION METHOD AND USES THEREOF DNASE1, DNA2, RNGTT ALDH1A1 599/4885MEN1 3900/4885GAA 115/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.